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Recommendations
1. To identify a person with diabetes at risk for foot ulceration, examine
the feet annually to seek evidence for signs or symptoms of peripheral
neuropathy and peripheral artery disease. (GRADE strength of recom-
mendation: strong; Quality of evidence: low)
2. In a person with diabetes who has peripheral neuropathy, screen for a
history of foot ulceration or lower-extremity amputation, peripheral artery
disease, foot deformity, pre-ulcerative signs on the foot, poor foot hygiene
and ill-fitting or inadequate footwear. (Strong; Low)
3. Treat any pre-ulcerative sign on the foot of a patient with diabetes. This
includes removing callus, protecting blisters and draining when necessary,
treating ingrown or thickened toe nails, treating haemorrhage when
necessary and prescribing antifungal treatment for fungal infections.
(Strong; Low)
4. To protect their feet, instruct an at-risk patient with diabetes not to walk
barefoot, in socks only, or in thin-soled standard slippers, whether at
home or when outside. (Strong; Low)
5. Instruct an at-risk patient with diabetes to daily inspect their feet and the
inside of their shoes, daily wash their feet (with careful drying particularly
between the toes), avoid using chemical agents or plasters to remove cal-
lus or corns, use emollients to lubricate dry skin and cut toe nails straight
across. (Weak; Low)
6. Instruct an at-risk patient with diabetes to wear properly fitting footwear
to prevent a first foot ulcer, either plantar or non-plantar, or a recurrent
non-plantar foot ulcer. When a foot deformity or a pre-ulcerative sign is
present, consider prescribing therapeutic shoes, custom-made insoles or
toe orthosis. (Strong; Low)
7. To prevent a recurrent plantar foot ulcer in an at-risk patient with diabe-
tes, prescribe therapeutic footwear that has a demonstrated plantar
pressure-relieving effect during walking (i.e. 30% relief compared with
plantar pressure in standard of care therapeutic footwear) and encourage
the patient to wear this footwear. (Strong; Moderate)
8. To prevent a first foot ulcer in an at-risk patient with diabetes, provide
education aimed at improving foot care knowledge and behaviour, as well
as encouraging the patient to adhere to this foot care advice. (Weak; Low)
9. To prevent a recurrent foot ulcer in an at-risk patient with diabetes, provide
integrated foot care, which includes professional foot treatment, adequate
footwear and education. This should be repeated or re-evaluated once
every 1 to 3 months as necessary. (Strong; Low)
SUPPLEMENT ARTICLE
Copyright © 2015 John Wiley & Sons, Ltd.
DIABETES/METABOLISM RESEARCH AND REVIEWS
Diabetes Metab Res Rev 2016; 32:(Suppl. 1) 16–24
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/dmrr.2696
10. Instruct a high-risk patient with diabetes to monitor
foot skin temperature at home to prevent a first or re-
current plantar foot ulcer. This aims at identifying the
early signs of inflammation, followed by action taken
by the patient and care provider to resolve the cause
of inflammation. (Weak; Moderate)
11. Consider digital flexor tenotomy to prevent a toe
ulcer when conservative treatment fails in a
high-risk patient with diabetes, hammertoes and
either a pre-ulcerative sign or an ulcer on the distal
toe. (Weak; Low)
12. Consider Achilles tendon lengthening, joint
arthroplasty, single or pan metatarsal head resec-
tion, or osteotomy to prevent a recurrent foot ulcer
when conservative treatment fails in a high-risk
patient with diabetes and a plantar forefoot ulcer.
(Weak; Low)
13. Do not use a nerve decompression procedure in an ef-
fort to prevent a foot ulcer in an at-risk patient with
diabetes, in preference to accepted standards of good
quality care. (Weak; Low)
Introduction
Foot ulcers are a major complication of diabetes mellitus,
with high morbidity, mortality and costs [1–3]. Yearly
incidence is estimated to be around 2%, but this in-
creases substantially when patients successfully heal
from a foot ulcer, with reported recurrence rates between
30% and 40% in the first year [4,5]. Prevention of these
ulcers is of paramount importance to reduce the patient
and economic burden.
Not all patients with diabetes are at risk for ulcera-
tion. Key risk factors include presence of peripheral neu-
ropathy, foot deformity, peripheral vascular disease or a
history of foot ulceration or amputation of (a part of)
the foot or leg [1,6,7]. In general, patients without any
of these risk factors do not appear to be at risk for ulcer-
ation. For the current guidance, we define the at-risk
patient in line with the definition from the International
Working Group on the Diabetic Foot (IWGDF) as ‘a
patient with diabetes who does not have an active foot
ulcer, but who has peripheral neuropathy, with or with-
out the presence of foot deformity or peripheral artery
disease, or a history of foot ulcer(s) or amputation of
(a part of) the foot or leg’ (Box 1).
In most countries with developed healthcare systems,
only patients at risk for ulceration are entitled to reim-
bursement for preventative foot care. Therefore, only in-
terventions aimed specifically at the prevention of ulcers
in at-risk patients are included in this guidance. Within
this group, those patients with a previous foot ulcer
and/or amputation are considered at higher risk for ulcer-
ation when compared with those without [1,6]. As such,
first foot ulcer and recurrent foot ulcer are considered as
separate outcomes of interest.
Various interventions for the prevention of foot ul-
cers are either used in clinical practice or have been
studied in scientific research. These include interven-
tions such as self-management, patient education,
therapeutic footwear, or foot surgery, or the combination
of two or more of these interventions into integrated
foot care.
In this guidance document, recommendations are
given for each intervention separately and include a ra-
tionale of how we came to each recommendation.1 This
rationale is based on a systematic review of the litera-
ture that underlies this guidance [8], together with a
consideration of benefits and harm, patients’ values
and preferences, and costs related to the intervention.
1Recommendations in this guidance were formulated based on the
Grading of Recommendations Assessment, Development and Evalua-
tion (GRADE) system for grading evidence when writing a clinical
guideline [68]. For much of the older data found in the systematic
review underlying this guidance, we could not calculate or assess
for inconsistency, indirectness or imprecision, which are needed to
fully assess the quality of evidence. Therefore, we decided to assess
the quality of evidence on the risk of bias of included studies, effect
sizes, and expert opinion, and rate the quality of evidence as ‘high’,
‘moderate’ or ‘low’. We assessed the strength of each recommendation
as ‘strong’ or ‘weak’, based on the quality of evidence, balance
between benefits and harm, patient values and preferences, and costs
(resource utilization). The rationale behind each recommendation is
described in this guidance.
Box 1. IWGDF definitions
Peripheral
neuropathy
The presence of symptoms or signs of
peripheral nerve dysfunction in people
with diabetes, after exclusion of other
causes
Loss of protective
sensation
Inability to sense light pressure,
for example, as applied with a 10 g
Semmes–Weinstein monofilament
Foot deformity Structural abnormalities of the foot such
as hammer toes, mallet toes, claw toes,
hallux valgus, prominent metatarsal heads,
residuals of neuro-osteoarthropathy,
amputations or other foot surgery
Peripheral artery
disease
Obstructive atherosclerotic vascular disease
with clinical symptoms, signs or
abnormalities on non-invasive vascular
assessment, resulting in disturbed or
impaired circulation in one or more
extremities
Therapeutic
footwear
Some form of customization to the patients
foot regarding insole, shoe and/or orthosis
Note: for all IWGDF definitions go to www.iwgdf.org.
Abbreviation: IWGDF, International Working Group on the Diabetic
Foot.
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General recommendations
Should a person with diabetes be
screened for foot ulcer risk?
1. To identify a person with diabetes at risk for foot ulcer-
ation, examine the feet annually to seek evidence for
signs or symptoms of peripheral neuropathy and
peripheral artery disease. (GRADE strength of recom-
mendation: strong; Quality of evidence: low)
Rationale
To prevent foot ulceration among patients with diabetes,
identification of those at risk for a foot ulcer is essential.
Foot examination is an easy method to achieve this goal
and should specifically include screening for the loss of
protective sensation caused by peripheral neuropathy
and for signs or symptoms of peripheral artery disease
(PAD), as discussed in the IWGDF guidance on PAD [9].
Even though evidence for a screening interval is lacking,
we recommend a yearly screening for a patient who is
not at risk for ulceration.
What should an at-risk person with
diabetes be screened for?
2. In a person with diabetes who has peripheral neuropa-
thy, screen for a history of foot ulceration or lower-
extremity amputation, peripheral artery disease, foot
deformity, pre-ulcerative signs on the foot, poor foot
hygiene, and ill-fitting or inadequate footwear.
(Strong; Low)
Rationale
To identify a patient at risk for foot ulceration, screening
is essential. In a patient with signs or symptoms of pe-
ripheral neuropathy, foot examination should consist of
taking a detailed history of foot ulceration or lower-
extremity amputation and screening for the presence of
peripheral artery disease and foot deformities [1,7].
Other factors that are associated with foot ulceration that
should be screened for include pre-ulcerative signs on
the foot such as callus, blisters and haemorrhage, ill-
fitting or inadequate footwear and poor foot hygiene,
such as improperly cut toenails, unwashed feet, presence
of fungal infection and unclean socks [10–12]. Even
though evidence from controlled studies does not exist,
we advocate screening for these factors.
At-risk patients require more frequent foot screening
than patients who are not at risk. The aim of more fre-
quent screening is early identification of factors that can
increase the chances of developing a foot ulcer, followed
by providing appropriate preventative foot care. For
example, early diagnosis and treatment of pre-ulcerative
signs on the foot may prevent foot ulcers, as well as more
severe complications such as infection and hospitaliza-
tion. Even though evidence for the effectiveness of a
screening interval in at-risk patients does not exist, we
recommend the following screening frequency (Table 1):
Is the treatment of a pre-ulcerative sign
on the foot effective in preventing a
foot ulcer in an at-risk patient with
diabetes?
3. Treat any pre-ulcerative sign on the foot of a patient
with diabetes. This includes removing callus,
protecting blisters and draining when necessary,
treating ingrown or thickened toe nails, treating haem-
orrhage when necessary and prescribing antifungal
treatment for fungal infections. (Strong; Low)
Rationale
Pre-ulcerative signs on the foot, such as callus, blisters or
haemorrhage, appear to be a strong predictor of future
ulceration [10,12]. These signs require immediate treat-
ment by a foot care professional. The effectiveness of
treating these pre-ulcerative signs on the prevention of
a foot ulcer has not been directly investigated. Indirect
evidence of benefit is that removal of callus reduces
plantar pressure, an important risk factor for ulceration
[13,14]. The benefits of treatment of pre-ulcerative signs
by a trained foot care professional outweigh the poten-
tial harm of such treatment and come at relatively low
costs.
Table 1. The IWGDF Risk Classification System 2015 and pre-
ventative screening frequency
Category Characteristics Frequency
0 No peripheral neuropathy Once a year
1 Peripheral neuropathy Once every
6 months
2 Peripheral neuropathy with
peripheral artery disease
and/or a foot deformity
Once every
3–6 months
3 Peripheral neuropathy and
a history of foot ulcer or
lower-extremity amputation
Once every
1–3 months
Abbreviation: IWGDF, International Working Group on the Diabetic
Foot.
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What should an at-risk patient with
diabetes avoid when walking at home or
outside?
4. To protect their feet, instruct an at-risk patient with
diabetes not to walk barefoot, in socks only, or in
thin-soled standard slippers, whether at home or when
outside. (Strong; Low)
Rationale
No studies have been performed on the effect of walking
barefoot, in socks or in thin-soled standard slippers, on
risk of foot ulceration. However, there are many large pro-
spective studies that show that at-risk patients with diabe-
tes have elevated levels of mechanical plantar pressure
during barefoot walking, which are a significant indepen-
dent risk factor for foot ulceration and should therefore be
reduced [15]. In addition, walking barefoot, in socks or in
thin-soled standard slippers has other harmful effects in
at-risk patients with diabetes such as lack of protection
against thermal or external trauma.
What self-management interventions
should a patient perform on a regular
basis?
5. Instruct an at-risk patient with diabetes to daily inspect
their feet and the inside of their shoes, daily wash their
feet (with careful drying particularly between the
toes), avoid using chemical agents or plasters to re-
move callus or corns, use emollients to lubricate dry
skin and cut toe nails straight across. (Weak; Low)
Rationale
Although no evidence is available for any of these self-
management interventions in relation to the prevention
of a foot ulcer, they enable early detection of pre-
ulcerative signs on the foot and contribute to basic foot
hygiene. This is likely to help prevent a foot ulcer.
Is footwear effective in preventing a
first or recurrent non-plantar foot ulcer
in an at-risk patient with diabetes?
6. Instruct an at-risk patient with diabetes towear properly
fitting footwear to prevent a first foot ulcer, either plan-
tar or non-plantar, or a recurrent non-plantar foot ulcer.
When a foot deformity or a pre-ulcerative sign is
present, consider prescribing therapeutic shoes,
custom-made insoles or toe orthosis. (Strong; Low)
Rationale
One randomized controlled trial (RCT) with high risk of
bias showed a positive effect of therapeutic footwear on
the prevention of foot ulcers in at-risk patients, most of
whom had no ulcer history [16]. Another RCT with high
risk of bias showed a clear trend but no significant ef-
fect of shear-reducing insoles on preventing foot ulcers
[17]. A third RCT with low risk of bias showed that
digital silicon orthoses can significantly reduce first toe
ulcer incidence in at-risk patients with pre-ulcerative
lesions [18]. No controlled studies exist on the specific
role of footwear to prevent a non-plantar foot ulcer.
However, ill-fitting footwear has been identified as an
important cause of non-plantar foot ulceration [11],
suggesting that properly fitting footwear may reduce ul-
cer incidence. In properly fitting footwear, the shoe
should not be either too tight or too loose. The inside
of the shoe should be 1–2 cm longer than the foot.
The internal width should equal the width of the foot
at the metatarsal phalangeal joints (or the widest part
of the foot), and the height should allow enough room
for all the toes. Evaluate the fit with the patient in the
standing position, preferably at the end of the day.
Those patients with a foot deformity or a pre-ulcerative
sign may need further adaptations to their footwear,
which may include therapeutic footwear, custom-made
insoles or a toe orthosis.
We know little about the adherence of patients to wear-
ing properly fitting footwear before an ulcer has devel-
oped. Patients may value the role of properly fitting
footwear to prevent ulcers, but some still consider their
footwear to be the cause of their problems. Furthermore,
anecdotally, many patients prefer not to wear bulky
custom-made shoes when they have not yet experienced
a foot ulcer.
Is therapeutic footwear effective in
preventing a recurrent plantar foot
ulcer in at-risk patients with diabetes?
7. To prevent a recurrent plantar foot ulcer in an at-risk
patient with diabetes, prescribe therapeutic footwear
that has a demonstrated plantar pressure relieving ef-
fect during walking (i.e. 30% relief compared with
plantar pressure in standard of care therapeutic foot-
wear) and encourage the patient to wear this footwear.
(Strong; Moderate)
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Rationale
Two RCTs with very low risk of bias have demonstrated
that therapeutic footwear that has proven to effectively
offload to the foot can significantly reduce the risk of a
recurrent plantar foot ulcer, provided that the patient
wears the footwear [5,19]. Effect sizes were large
(46.1–63.6% relative risk reduction compared with stan-
dard of care therapeutic footwear), but effect may vary
across patients. These data confirm earlier findings in
three RCTs of mixed methodological quality on the effi-
cacy of therapeutic footwear: relative risk reductions
compared with control condition: 52.5–70.2% [16–18].
Another RCT, with low risk of bias, assessed the effect
of therapeutic insoles and did not show a significant
effect on ulcer recurrence compared with standard foot-
wear; the relative risk reduction was only 12% [20].
However, this study did not use insoles with proven effi-
cacy in offloading plantar pressure.
The benefits of continuously wearing footwear with a
proven offloading effect outweigh the potential harm;
available trials have infrequently reported any harm re-
lated to footwear. Clinicians should encourage patients
to wear prescribed footwear whenever possible. The costs
of prescribing therapeutic footwear with demonstrated
offloading effect may be quite high as it requires the mea-
surement of barefoot or in-shoe plantar pressure for
which equipment to date is relatively expensive. However,
these costs should always be regarded in association with
the benefit of ulcer prevention. Cost-effectiveness has not
been studied to date, but in our opinion, footwear de-
signed or evaluated using plantar pressure measurement
is likely to be cost-effective when it can reduce ulcer risk
by 50% (a risk reduction demonstrated in most of the
aforementioned trials on this topic).
This recommendation is predicated on the availability
of both therapeutic footwear and technology for pres-
sure measurement. Not in all regions and clinical set-
tings, however, plantar foot pressure can be measured.
For these cases, we recommend to prescribe therapeutic
footwear using available state-of-the-art scientific knowl-
edge on footwear designs that effectively offload the
foot.
Is patient education effective in
preventing a first foot ulcer in an at-risk
patient?
8. To prevent a first foot ulcer in an at-risk patient with di-
abetes, provide education aimed at improving foot care
knowledge and behaviour, as well as encouraging the
patient to adhere to this foot care advice. (Weak; Low)
Rationale
While the efficacy of patient education to prevent a first
foot ulcer has not been studied in a controlled trial design,
two large non-controlled studies showed convincingly
that those patients who are adherent to the advice given
in the education programme are at much lower risk of de-
veloping a first foot ulcer than those who are not adherent
[21,22]. Even though controlled studies on efficacy to pre-
vent a first foot ulcer have not been performed to date, we
believe that patients who are at risk for ulceration should
receive some form of education. Such education should
consist of information on foot complications and their
consequences, on preventative behaviour, such as wearing
adequate footwear and self-management of foot health,
and on seeking professional help in a timely manner when
patients identify a foot problem.
Is integrated foot care effective in
preventing recurrent foot ulcers in
at-risk patients with diabetes?
9. To prevent a recurrent foot ulcer in an at-risk patient
with diabetes, provide integrated foot care, which
includes professional foot treatment, adequate footwear
and education. This should be repeated or re-evaluated
once every 1 to 3 months as necessary. (Strong; Low)
Rationale
We define an integrated foot care programme as an inter-
vention that minimally includes professional foot care,
patient education and adequate footwear, which are re-
peated or re-evaluated on a regular basis. One RCT, one
non-randomized controlled trial and three non-controlled
studies all reported significantly lower percentages of
recurrent ulcers in patients who received integrated foot
care compared with those who did not [23,24], or in those
patients who were adherent to a programme compared
with those who were not [25–27]. None of the studies
reported any complications or other harm related to the
programme.
Professional foot care, by a professional trained in
diabetic foot problems, can consist of callus removal,
drainage of large blisters, protection of small blisters,
treatment of ingrown or thickened nails, treatment of
haemorrhage or antifungal treatment for fungal infec-
tions, as necessary. Patient education should be repeated
regularly, as two RCTs [28,29] demonstrated no effect
on ulcer prevention of a single session of patient educa-
tion. Education should be aimed at improving foot care
knowledge and behaviour, as well as offering the patient
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support in adhering to this advice. For suggestions on ad-
equate footwear see Recommendations 6 and 7. There is
no information available on costs and cost-effectiveness
of integrated foot care. A recent publication from the US
suggested that there was an increase in hospital admis-
sions for a diabetic foot ulcer after Medicare cancelled
financial coverage in one US state for preventative treat-
ment given by podiatrists [30].
Is self-management of foot health
effective in preventing a first or
recurrent foot ulcer in at-risk patients
with diabetes?
10. Instruct a high-risk patient with diabetes to monitor
foot skin temperatures at home to prevent a first or re-
current plantar foot ulcer. This aims at identifying the
early signs of inflammation, followed by action taken
by the patient and care provider to resolve the cause
of inflammation. (Weak; Moderate)
Rationale
Self-management of foot health is considered by many to
be an important component of foot care in at-risk patients
with diabetes. Self-management can include many inter-
ventions, but we found no evidence to support any specific
intervention, with the exception of home monitoring of
foot skin temperature. Three RCTs, either with low or very
low risk of bias, showed that monitoring of plantar foot
skin temperature on a daily basis with an easy-to-use infra-
red thermometer, combined with subsequent preventative
actions when elevated temperatures were noted, is
effective over standard treatment to prevent foot ulcers
in high-risk patients (IWGDF risk classification 2 or 3;
[31–33]). As all three RCTs were from the same research
group, generalizability of these findings is uncertain.
Professionals may value home monitoring as an easy-to-
use and relatively inexpensive method, with potentially
high clinical value, empowering patients in the care of their
own feet. However, adherence was an important factor in
the conducted RCTs, and patients, in particular those
who have not had a foot ulcer, may find the requirement
for daily assessment a burden. False-positive and false-
negative outcomes of temperature measurements may un-
necessarily concern or stress patients and affect their confi-
dence in this approach [34]. To our knowledge, home
monitoring of foot temperature is currently not imple-
mented in foot care of high-risk patients with diabetes,
which may be related to patient values or preferences, lack
of easy access to calibrated equipment, lack of information
on cost-effectiveness and implementation feasibility.
Are surgical interventions effective in
preventing a foot ulcer in at-risk
patients?
11. Consider digital flexor tenotomy to prevent a toe ulcer
when conservative treatment fails in a high-risk patient
with diabetes, hammertoes and either a pre-ulcerative
sign or an ulcer on the distal toe. (Weak; Low)
Rationale
Seven retrospective case series of percutaneous digital
flexor tendon tenotomy performed to heal distal toe ulcers
noted recurrence rates ranging between 0% and 20% in a
total 231 treated patients, over a mean follow-up between
11 and 36 months [35–41]. Four of these studies also re-
ported on the effects of flexor tendon tenotomy of a toe
where no ulcer was present at the time of the procedure.
In a cumulative total of 58 patients with impending ulcers
(i.e. abundant callus on tip of the toe or thickened nails),
no ulcer occurrence was found in a mean 11–31 months
follow-up [37,38,40,41]. While controlled studies on this
topic are lacking, we consider this a promising procedure
in a patient who has a distal toe ulcer, or a pre-ulcerative
sign on the distal toe, that fails to respond to conservative
treatment and requires normalization of foot structure to
prevent ulceration.
The possible benefits of digital flexor tenotomy likely
outweigh the harm, as few complications have been re-
ported. Patients who have pre-ulcerative lesions for
which they have frequent conservative treatment that
does not improve outcome may value and prefer treat-
ment by flexor tenotomy. The procedure is easily per-
formed in an outpatient setting, with no need for
subsequent immobilization, and is not likely to negatively
affect foot function. Costs and cost-effectiveness of this
procedure have not been evaluated. Possible adverse
effects of the surgery, although minimal, should be
discussed with the patient.
12. Consider Achilles tendon lengthening, joint
arthroplasty, single or pan metatarsal head resection
or osteotomy to prevent a recurrent foot ulcer when
conservative treatment fails in a high-risk patient with
diabetes and a plantar forefoot ulcer. (Weak; Low)
Rationale
Primarily aimed at healing recalcitrant forefoot plantar ul-
cers, one RCT (with low risk of bias) and several non-
controlled studies have shown a positive effect of Achilles
tendon lengthening in preventing ulcer recurrence in the
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short and long term, with generally large effect sizes [42–
48]. One small RCT (with low risk of bias) [49], two ret-
rospective cohort studies (with varying risk of bias)
[50,51] and several non-controlled studies [52–56] found
efficacy of single or pan metatarsal head resections to
prevent ulcer recurrence, with generally large effect sizes
found. One retrospective cohort study with high risk of
bias and two small non-controlled studies showed low ul-
cer recurrence rates after metatarsal-phalangeal or inter-
phalangeal joint arthroplasty [57–59]. One retrospective
cohort study on osteotomy showed a non-significant
60% reduction in ulcer recurrence compared with con-
servative treatment, while one non-controlled study
showed no ulcer recurrence after osteotomy [60,61].
While effect sizes are often large, very few studies show
the efficacy of these interventions in well-designed con-
trolled studies.
Possible complications and side effects of these surgical
offloading techniques include post-operative infection,
new deformities, gait problems and transfer ulcers
[42,62]. Therefore, it is not clear if the benefits outweigh
the harm. In any case, these techniques should be primar-
ily used in patients to heal a foot ulcer that is recalcitrant
to conservative treatment and that is expected to have
high risk of recurrence if the foot structure is not changed.
Patient values and preferences for these approaches are
unknown, although we expect patients to value an inter-
vention as high when it can prevent ulcers, but as low
when it causes complications such as significant gait or
balance problems. The costs of surgical interventions can
be much higher than for conservative treatment, but
cost-effectiveness is unknown. Clinicians should carefully
discuss possible adverse effects of the surgery with the
patient.
13. Do not use a nerve decompression procedure in an ef-
fort to prevent a foot ulcer in an at-risk patient with
diabetes, in preference to accepted standards of good
quality care. (Weak; Low)
Rationale
We found two retrospective cohort studies with high
risk of bias and three non-controlled studies that inves-
tigated nerve decompression in the prevention of foot
ulcers in at-risk patients with diabetes [63–67]. Al-
though with positive results (one retrospective cohort
study reported a significantly lower ulcer incidence in
the operated leg compared with the contralateral non-
operated leg of the same patient), the risk of bias of
these studies was high, information on post-operative
complications was scarce and (most importantly) nerve
decompression was not compared with accepted
standards of good quality preventative care. Most stud-
ies were also from the same research group, further lim-
iting the generalizability of these results. With various
non-surgical interventions available that can be con-
sidered standard of good quality care to prevent a foot
ulcer in an at-risk patient, nerve decompression should
not be used, until more evidence for its efficacy com-
pared with conservative treatment is obtained from
appropriately designed controlled studies.
Key controversies
1. Peripheral neuropathy is the most important risk fac-
tor for the development of foot ulcers in patients with
diabetes, but research on the prevention or treatment
of neuropathy is relatively scarce. A stronger research
focus in this area is needed.
2. Robust data are lacking on whom, how and when to
screen for the risk of foot ulceration. High-quality data
on the benefit of interventions to prevent a first foot ulcer
are scarce. As the event rate (foot ulceration) is relatively
low in a populationwithout a previous ulcer, large groups
of patients need to be targeted, and it is unclear if the
benefits will outweigh harm and costs. Studies are ur-
gently needed to better define the categories of patients
that will benefit from preventative interventions and
what specific types of interventions should be included.
3. Costs and cost-effectiveness have not been investigated
for any of the interventions described in this guidance,
and more attention to cost aspects is warranted.
4. The vast majority of studies underlying this guidance
are single intervention studies, yet preventative foot
care for at-risk patients with diabetes nearly always
consists of an integrated care approach. While studies
on integrated foot care show some evidence of effec-
tiveness in preventing a recurrent ulcer, unfortunately,
the exact content of this integrated strategy is fre-
quently poorly described, hampering generalizability
to other settings.
5. Adherence to an intervention has been shown to be
crucial in preventing foot ulcers [5,22,25,26,33]. It is
consistently reported that patients who do not adhere
present with higher rates of ulceration. A stronger
focus is urgently needed on development, evaluation
and implementation of methods that improve adherence
to preventative diabetic foot treatment.
6. While there is some evidence to support surgical inter-
ventions for the prevention of a recurrent ulcer in se-
lected patients, these interventions are not without
risk. The exact role of these surgical procedures com-
pared with conservative approaches in the prevention
of ulceration is still unclear and requires appropriately
designed controlled studies.
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